Advanced in Primary T Cell Immunodeficiency

Christine Bodemer

Paris, FR 
Advanced in Primary T Cell Immunodeficiency
Paris, FR 
OverviewLocationsClinical Research

Overview

Christine Bodemer practices in Paris, France. Ms. Bodemer is rated as an Advanced expert by MediFind in the treatment of Primary T Cell Immunodeficiency. Her top areas of expertise are Epidermolysis Bullosa, Juvenile Dermatomyositis, Incontinentia Pigmenti, Dermatomyositis, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 304 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Primary T Cell Immunodeficiency.

Gender
Female

Locations

Paris, France
Other Locations
Garches, France
149 Rue De Sèvres, Paris, Eu, 75015, France
Creteil, France
Nancy, 54000, France
Bordeaux, France
Saint-jean-saint-germain, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Evaluation of Basal Tryptasemia According to Age in a Pediatric Control Population
Evaluation of Basal Tryptasemia According to Age in a Pediatric Control Population
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Other
Multicentre, Open-label, Uncontrolled, Pivotal Clinical Trial to Confirm the Efficacy and Safety of Autologous Fibrin-cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified for Restoration of Epidermis in Patients With Junctional Epidermolysis Bullosa
Multicentre, Open-label, Uncontrolled, Pivotal Clinical Trial to Confirm the Efficacy and Safety of Autologous Fibrin-cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified for Restoration of Epidermis in Patients With Junctional Epidermolysis Bullosa
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Transplantation
Study Phase: Phase 2/Phase 3
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene
A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene
Enrollment Status: Terminated
Publish Date: August 25, 2021
Intervention Type: Drug
Study Drug: QR-313
Study Phase: Phase 1/Phase 2
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

304 Total Publications

Methodological Concerns in the EASE Study of Oleogel-S10 for Epidermolysis Bullosa: reply from authors.
Methodological Concerns in the EASE Study of Oleogel-S10 for Epidermolysis Bullosa: reply from authors.
Journal: The British journal of dermatology
Published: September 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bodemer's expertise for a condition
ConditionClose
View All 23 Distinguished Conditions
View All 34 Advanced Conditions
View All 112 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile